Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

anti-VEGF protein therapeutic

Home Drugsanti-VEGF protein therapeutic

anti-VEGF protein therapeutic

Unknown Manufacturer

Generate AI report

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

BISPECIFIC ANTIBODY SPECIFICALLY BINDING TO TIE2 AND VEGF, AND USE THEREOF
Applicant: MABTICS CO LTDPriority: 2024
WO
VEGF (vascular endothelial growth factor) combined oligopeptide and application thereof in preparation of anti-angiogenesis therapeutic drugs
Applicant: SHENYUAN ZHIYAO BIOTECHNOLOGY BEIJING CO LTDPriority: 2025
CN
Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
Applicant: REGENERON PHARMAPriority: 2009
US
2 publications
Pharmaceutical composition containing, as active ingredient, fusion protein in which tumor-penetrating peptide and anti-angiogenesis agent are fused, for preventing and treating cancer or angiogenesis-related diseases
Applicant: IL DONG PHARMAPriority: 2015
US
METHOD FOR TREATING OR PREVENTING EYE DISEASE
Applicant: GAN & LEE PHARM CO LTDPriority: 2024
WO
A STABLE LIQUID FORMULATION OF FUSION PROTEIN WITH IGG FC DOMAIN
Applicant: ALTEOGEN INCPriority: 2015
CN
EP
US
5 publications
STABLE LIQUID FORMULATION OF FUSION PROTEIN HAVING IGG FC DOMAIN
Applicant: ALTEOGEN INCPriority: 2024
WO
NOVEL FUSIONS PROTEINS FOR EXTENDED HALF-LIFE OF VEGF BINDING PROTEINS
Applicant: NAVIGO PROTEINS GMBHPriority: 2025
EP